BioMed Research International / 2013 / Article / Tab 1

Review Article

Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 1

Current HCV NS3-4A protease inhibitors/drugs in pipeline (/r means boosted by ritonavir).

MechanismInhibitor nameGenotypic coverageDaily dosingCompanyStatus

Reversible covalent inhibitorIncivek (telaprevir, VX-950) 1 Three timesVertexApproved
Victrelis (boceprevir, SCH503034) 1 Three timesMerckApproved

Noncovalent inhibitorABT-450/r1OnceAbbottPhase III
Simeprevir (TMC435)1, 2, 5, and 6OnceJanssenPhase III
Faldaprevir (BI201335)1OnceBoehringer IngelheimPhase III
Danoprevir (RG7227)1TwiceGenentechPhase II
Vaniprevir (MK-7009)1TwiceMerckPhase II
MK-51721, 2OnceMerckPhase II
Asunaprevir (BMS-650032)1, 4OnceBristol-Myers SquibbPhase II
ACH-16251OnceAchillionPhase II
GS-92561TwiceGileadPhase II
ACH-26841, 3OnceAchillionPhase II
GS-94511a, 1bOnceGileadPhase II
Narlaprevir/r1OnceMerckPhase II
IDX3201, 1b, 3a, and 4aOnceIdenixPhase II

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.